Verge Genomics, Eli Lilly partner to develop ALS therapies
Verge Genomics has announced a three-year partnership with Eli Lilly and Company to discover and develop novel therapies for amyotrophic lateral sclerosis (ALS), a motor neuron disease. As
Altesa Biosciences has signed an exclusive worldwide license agreement with biotechnology firm Vaxart for the development and commercialisation of the latter’s patented formulation of the capsid-binding Vapendavir antiviral.
Global biopharmaceutical firm Sanofi has launched a dedicated vaccines mRNA Center of Excellence to accelerate development and delivery of next-generation vaccines. The company has also announced plans to